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Background: To compare proton beam therapy (PBT) and intensity-modulated radiation therapy (IMRT) with conformal
radiation therapy (CRT) in terms of their organ doses and ability to cause secondary cancer in normal organs.
Methods: Five patients (median age, 4 years; range, 2–11 years) who underwent PBT for retroperitoneal neuroblastoma
were selected for treatment planning simulation. Four patients had stage 4 tumors and one had stage 2A tumor,
according to the International Neuroblastoma Staging System. Two patients received 36 Gy, two received 21.6 Gy, and
one received 41.4 Gy of radiation. The volume structures of these patients were used for simulations of CRT and IMRT
treatment. Dose–volume analyses of liver, stomach, colon, small intestine, pancreas, and bone were performed for the
simulations. Secondary cancer risks in these organs were calculated using the organ equivalent dose (OED) model,
which took into account the rates of cell killing, repopulation, and the neutron dose from the treatment machine.
Results: In all evaluated organs, the mean dose in PBT was 20–80% of that in CRT. IMRT also showed lower mean doses
than CRT for two organs (20% and 65%), but higher mean doses for the other four organs (110–120%). The risk of
secondary cancer in PBT was 24–83% of that in CRT for five organs, but 121% of that in CRT for pancreas. The risk of
secondary cancer in IMRT was equal to or higher than CRT for four organs (range 100–124%).
Conclusion: Low radiation doses in normal organs are more frequently observed in PBT than in IMRT. Assessments of
secondary cancer risk showed that PBT reduces the risk of secondary cancer in most organs, whereas IMRT is associated
with a higher risk than CRT.
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Neuroblastoma is the most common extracranial solid tu-
mor, accounting for >7% malignancies in patients >15 years.
Approximately 40% patients present with retroperitoneal
mass involving the adrenal gland or neural ganglion. A
multi-disciplinary approach is normally established to
treat the disease. Postoperative radiotherapy for the pri-
mary site plays a major role in decreasing the recurrence
of diseases for advanced stage patients with high-grade* Correspondence: h.fuji@scchr.jp
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stated.histology. However, concerns about late adverse events in
irradiated organs remain for survivors of the disease.
More than 90% survivors have been reported to suffer
from one or more treatment-related event(s) [1].
Although the incidence of secondary cancer in patients
with neuroblastoma is not high, it is a profound issue
for patients. The reported mortality rate is ten times
higher than that of the general population [2]. Therefore,
reducing secondary cancer risk from radiotherapy is a
major goal of the development of neuroblastoma treat-
ment as well as those of other pediatric cancer [3,4].
Recent advanced techniques of radiotherapy allow the
radiation oncologist to optimize the treatment without. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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tional radiotherapy (CRT) for retroperitoneal neuroblast-
oma poses a large dose bath outside the target and
deposits high doses to normal organs. Compared with
CRT, recent advanced techniques, such as intensity-
modulated radiotherapy (IMRT) and proton beam ther-
apy (PBT), are known to provide superior conformal
dose distribution for large, irregularly shaped tumors.
There are a few reports that characterize these treat-
ments for neuroblastoma [5-9]. However, the dose vol-
ume profiles of normal organs in these reports were not
consistent or large enough to generalize the technique
replacing conventional radiotherapy. Furthermore, we
have little knowledge to interpret the superiorities of
their dose volume profiles with respect to clinical advan-
tages because the doses of analyzed organs were lower
than the ablative dose for the organs, in most cases re-
gardless of treatment techniques.
Recently, surveys of cancer survivors and analysis of
their treatment have enabled estimation of the risk of
secondary cancer by radiotherapy [10-14]. The method
consists of unique dose–response curves and effective
tools for estimating the clinical significance of a wide
range of doses. The model also includes estimation of
the neutron dose [15].
The purpose of this study was to compare the dose–
volume parameters in several organs from PBT, IMRT,
and CRT. Based on the dose volume analysis, an estima-
tion of secondary cancer risks in these organs was per-
formed using the organ equivalent dose (OED) model,
which took into account the rates of cell killing, repopula-
tion, and the neutron dose from the treatment machine.
Patients and methods
This study was based on treatment planning data for five
patients (median age, 4 years; range, 2–11 years) who
underwent PBT for truncal neuroblastoma at our hos-
pital from July 2003 to October 2010. According to the
International Neuroblastoma Staging System, four chil-
dren were classified as class IV and one as class II. The
tumor was eliminated in three patients, but microscopic
residual disease was reported. The rest of two patients
were determined to be inoperable after chemotherapyTable 1 Patient characteristics
Case
no.
Age (y) /Gender Site INSS
1 4/F Rt. Retroperitoneum 4
2 11/M Upper abdomen Mediastinum 4
3 5/M Upper abdomen Mediastinum 4
4 2/F Lt. Adrenal 4
5 2/F Lt. Adrenal 2Aand one of them were recurrent disease. The targeted
areas of these patients was bilaterally extended in two
patients and unilaterally localized in three. Of the pa-
tients with unilateral lesions, two were left-sided one
was right-sided. Characteristics of the patients were
shown in Table 1. This study was approved by the Insti-
tutional Review Board of our institute, and informed
consent was waived because of the retrospective nature
of the study.
Proton beam therapy (PBT)
All patients underwent PBT to the tumor bed and tumor
itself, if it existed. The proton beam was delivered using
a rotational gantry system for two to five directions of
the beam. The patients were immobilized by vacuum fix-
ation bag during treatment sessions. Orthogonal fluoros-
copy was used before every treatment session to verify
beam localization. Radiation doses of 21–41 Gy were
delivered, depending on the clinical stage, status of
remaining tumor, and previous treatment. Taking into
account the relative biological effect of a proton beam,
the dose was reported in gray, Gy (relative biological ef-
fectiveness, RBE), which is equivalent to the physical
dose in Gy multiplied by 1.1.
Computed tomography (CT) dedicated to treatment
planning was obtained before treatment and fused with
CT images and magnetic resonance images obtained be-
fore surgery. The combination of images allowed specifi-
cation of the gross target volume (GTV), which consisted
of the tumor bed and areas of residual disease. 131Iodine
metaiodobenzylguanidine (MIBG) scintigraphy was per-
formed to define the residual tumor in some cases. The
clinical target volume (CTV) was created by expanding
the GTV by 1–2 cm. If residual disease was subjected to
boost irradiation, a CTV for the boost was created for the
residual disease. Margins of 2–3 mm were added to the
CTVs for initial irradiation and boosting irradiation to ob-
tain the planning target volume.
The parameters of objectives are shown in Table 2. We
planned to deliver a prescribed dose to the isocenter of
the CTV. The minimum and maximum doses in the CTV
were determined to be 80% and 110% of the prescribed









- High Inoperable 147 41.4
- High Recurrence 105 36
- High Complete resection 172 21.6
48 High Gross total resection 464 21.6
217 High Subtotal resection 108 36
Table 2 Dose profiles of each organs
Dose (Gy) Fraction of cases decrease
with respect to CRT (%)
CRT IMRT PBT IMRT PBT
Liver Mean 14.2 13.3 6.3 60 100
D 5% 32.1 25.3 22.8 100 100
D50% 10.0 12.8 3.5 40 100
D90% 2.8 4.1 0.2 0 100
Stomach Mean 20.3 21.5 11.8 60 80
D 5% 32.9 31.7 20.4 80 100
D50% 17.7 20.7 5.0 60 100
D90% 10.5 13.5 2.2 40 100
Small intestine Mean 9.4 11.2 3.4 20 100
D 5% 31.4 30.6 21.7 60 100
D50% 3.7 7.6 1.4 40 100
D90% 0.7 1.1 0.0 0 100
Bone Mean 20.5 21.7 16.9 20 80
D 5% 32.2 33.0 27.5 0 100
D50% 21.8 24.7 7.7 40 100
D90% 1.3 4.3 0.1 0 100
Pancreas Mean 28.2 28.2 21.2 60 80
D 5% 32.3 33.2 30.6 20 100
D50% 31.5 31.1 20.9 60 80
D90% 17.0 16.8 11.9 40 80
Colon Mean 9.9 11.2 2.1 60 100
D 5% 31.8 26.6 14.0 100 100
D50% 8.5 10.4 0.1 20 100
D90% 0.7 0.9 0.0 0 100
Figure 1 RED corresponding with organ dose. The linear–
exponential curves may have a plateau or a decline in RED at
higher dose.
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beam configuration, the kidney dose was limited to a des-
ignated constraint dose: 12 Gy of mean dose.
Doses of other organs, including stomach, liver, small
intestine, and rectum were also considered in the beam
configuration process. Symmetric irradiation of the ver-
tebral body was also taken into account to prevent
asymmetric bone growth. Of each vertebral body, the
differences in lateral edges of the vertebral body were
limited to <4 Gy, 10–20% of prescribed dose. The total
of 2–3 ports were used for a patient.
Planning for simulation and dose comparison
These axial CT data sets with structures, which were used
for planning photon beam treatment, were transferred to
the Pinnacle (Phillips Medical Systems, Fitchburg, WI)
treatment planning system. Identical objectives for dose
delivery to target and organs at risk were applied for
optimization of the CRT and IMRT treatment plans. The
CRT planning was used opposed anterior-posterior and
posterior-anterior beams. The IMRT plan was developedusing inverse treatment planning. A total of 4–7 beams se-
lected from 18 gantry angles were used with a 0.5 cm ×
0.5 cm minimum beam resolution.
Evaluation of risks of secondary cancer
Secondary cancer risk at the organs of interest was cal-
culated using a mechanistic model of carcinogenesis in-
cluding cell killing and fractionation effects [10-14].
Dose–volume histograms were computed for liver,
stomach, colon, small intestine, pancreas, and bone for all
patients and all treatment techniques, using the treatment
planning system. The dose–volume histograms were cor-
rected for neutron dose on the basis of neutron dose mea-
surements at the used proton beam line [16]. The dose
response relationship for radiation induced cancer, in this
work called risk equivalent dose (RED), was taken from
[10] for the organs plotted in Figure 1. It is defined as
RED Dð Þ ¼ e
−α 0D
α 0R
1− 2Rþ R2eα 0D− 1−Rð Þ2e−α 0R1−R D
 
Where D is the dose, and α and R are organ-specific
model parameters taken from [10].
The organ equivalent dose (OED), which is a generalized
dose average weighted with the dose–response curve for
second cancer induction (RED) and thus proportional to
the probability for the induction of a malignancy [11], was
calculated from the dose–volume histograms:
OEDorgan ¼ 1VT ∑i V Dið ÞRED Dið Þ
where VT is the total organ volume and V(Di) the dose–
volume histogram,. OED values are age independent and
can be used to compare different treatment plans with re-
gard to the organ- and plan-specific secondary cancer in-
duction rate.
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exposure (agex) and increases with decreasing agex. Be-
cause the patients studied in this work were very young,
we decided to compute absolute risk estimates in terms
of lifetime attributable risk (LAR), although the LAR
presented might be subject to large errors. The LAR was





 γe agex−30ð Þ þ 1n
agex
70
   S ageað Þ
S agexð Þ dagex
where S is the survival function for a standard population,
taken from report of Kellerer et al., β is the cancer induc-
tion rate in percent per person per gray for low dose, and
γe and γa are organ-specific parameters taken from the
atomic bomb survivor data [10]. The integration is taken
over the attained age agea. LAR is then the lifetime attrib-
utable cancer risk for a patient treated with the treatment
plan/technique in question at agex.
Results
Dosimetric comparisons
The common prescribed dose to the target and the
doses to the organs for all three treatment techniques
are shown in Table 2. Among the five organs, the mean
dose to the liver in IMRT was lower than that in CRT,
although the difference is not statistically significant. De-
creases in high dose deposition by IMRT were more
prominent than that of low dose deposition. In three of
five patients, IMRT reduced D5% of liver, stomach, small
intestine, and colon. However, the fraction of patients
that showed decreases in D90% in all organs was less
than half. The mean doses to stomach, bone, and colon
were significantly lower in PBT than in CRT. The de-
crease in deposited dose by PBT was seen across a wide
range (i.e., D5%, D50%, and D90%), except in pancreas.
The representative dose distribution map and dose
volume histograms of the three treatment techniques areCRT IMR
Figure 2 Dose distributions map of CRT, IMRT and PBT for representa
and 10%(blue) of prescribed dose were shown in CT image.shown in Figures 2 and 3. PBT and IMRT had compar-
able coverage of the target with the prescribed dose and
a substantial decrease in volume of dose compared with
CRT. IMRT can be characterized as having a larger frac-
tion of organs irradiated at a lower dose compared with
CRT. The dose–volume histogram of PBT demonstrated
a lower fraction for high dose and low dose deposition.Secondary cancer risk
The ratios of secondary cancer risk in IMRT were 0.95
for liver, 1.00 for stomach, 1.03 for bone, 1.24 for colon,
1.14 for pancreas, and 0.81 for the small intestine. The
ratios of secondary cancer risk in PBT were 0.49 for
liver, 0.83 for stomach, 0.79 for bone, 0.24 for colon,
1.21 for pancreas, and 0.36 for the small intestine. The
estimated secondary cancer risks in IMRT were lower
than those in CRT for two of the five organs. The esti-
mated secondary cancer risks for the other three organs
in IMRT were equal to or higher than those in CRT.
The estimated secondary cancer risk in PBT was lower
in all organs except pancreas (Figure 4).Discussion
Three radiotherapy techniques, CRT, IMRT, and PBT,
were compared in terms of delivered dose and estimated
risks secondary cancer for normal organs. We found that
IMRT has marginal advantages in dose reduction when
compared with CRT. The general replacement of CRT
with IMRT in the treatment of neuroblastoma is contro-
versial. Paulino reported a substantial variation in
organ–dose reduction effect with IMRT in neuroblast-
oma treatment [10]. Their analysis demonstrated that
IMRT increased the dose to normal organs in cases with
extending disease or with specific beam configurations.
The recent report comparing tomotherapy and 3D CRT
also demonstrated inconsistent benefits of IMRT [6]. In
their analysis, the volume irradiated at high dose is in-
clined to be low in IMRT, but the volume irradiated at a
low dose in IMRT is larger than that in CRT. This pro-
pensity was also observed in the current study.T PBT
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Figure 3 Dose volume histograms of CRT, IMRT and PBT. Dose volume histograms were compared among three treatment techniques for
CTV and six organs.
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from IMRT in normal organ dose reduction, others pa-
tients derive apparent benefit from IMRT after prior simu-
lation to select the appropriate treatment technique. The
priority of adverse event reduction and the dose-volume
parameter to limit the adverse event among variety of or-
gans are uncertain. When the priority of dose-volume par-
ameter are established, it becomes clear that the flexibility
of dose delivery in IMRT makes it more effective.
We found that dose to organs in PBT was lower than
those deposited by CRT. The superiority of PBT in neuro-
blastoma treatment compared with CRT was reported in
2001 [7]. The results of the current study, which included
patients of varying size and sites, emphasize the usefulness
of an early simulation study.
In contrast to IMRT, the reduction of dose to normal
organs in PBT is observed at a wide range of dose.
Therefore, dose reduction in PBT expected to be robust
compared with IMRT.
Comparing dose reduction between IMRT and PBT is
the theme of recent focus. Hattangi reported that PBT de-





Ratio of IMRT to CRT
Ratio of PBT to CRT
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Figure 4 Mean doses and REDs for evaluated organs. Ratio of mean orcompared with IMRT [5]. The current study confirmed
the decrease in deposited dose to liver and stomach, and
showed that the colon and small intestine also showed a
decrease in deposited dose in PBT compared with IMRT.
Comparing several dose levels in both PBT and IMRT,
PBT showed more apparent decreases in the low and mid-
dle dose levels. Therefore, the dose reduction of PBT is ex-
pected to be robust compared with IMRT.
Among the five patients in the current study, three
cases extended to the retroperitoneum and the clinical
target volume of these cases included the pancreas. The
organ involved in the designated CTV cannot avoid ir-
radiation, even with a conformal radiotherapy technique
such as IMRT or PBT.
We introduced the secondary cancer risk estimation to
establish the clinical significance of conformal treat-
ment techniques. For secondary cancer, most clinical
data show a linear–exponential relationship. Linear–
exponential models were proposed as a result of analysis
of cancer incidence in patients who underwent radio-
therapy for Hodgkin lymphoma [12]. The concept of in-
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B
gan doses (A) and RED (B) for IMRT and PBT to those for CRT.
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dose range used in this analysis to the therapeutic dose de-
creases the uncertainties in exploration of their formula.
The difference between IMRT and PBT is more apparent
in secondary cancer risks, which is obtained by comparing
mean doses of organs. The outcome can be used to argue
that PBT is more widely applicable.
There are a few reports on estimation of secondary
cancer risks using deposited dose to target. Zhang et al.
reported the risk of secondary cancer after craniospinal
irradiation for medulloblastoma [17]. They report the risk
of secondary cancer using a variety of curves for dose–
response between deposited dose and excessive relative
risk. With variety of formulas for estimating excess absolute
risk, including a linear relationship, the ratio of secondary
risk was reduced by factor of 0.055–0.36 using PBT com-
pared with using IMRT in medulloblastoma treatment.
Yoon, et al. also simulated craniospinal irradiation with
the OED model. They also demonstrated that it decreased
the risk of secondary cancer. However, the estimation of
cancer risk in their report does not account for differences
among organs [18]. The model used in the current study
is based on a dedicated linear–exponential curve for each
organ, including the parameters extracted from the survey
of atomic bomb survivors. Therefore, the estimated num-
bers are more reasonable with the available data.
The current study demonstrated the discrepancy be-
tween the estimated secondary cancer risk of organs and
the deposited dose of the organs. The mean dose to the
pancreas in IMRT and PBT was lower than that in CRT.
However, the estimated risk of secondary cancer in the
pancreas with IMRT and PBT is higher than in CRT.
Generally, optimization is performed during treatment
planning to reduce the dose to normal organs. However,
with the OED model, irradiation of organs with a higher
dose, over the inflection point, does not necessary in-
crease secondary cancer risk compared with lower dose
irradiation. While increasing the dose to a normal organ
may favor the reduction of cancer risk under particular
conditions, it is thought to increase the risk of functional
ablation of the organ [18]. Therefore, we should be care-
ful about increasing the organ dose based on the esti-
mated risks of secondary cancer.Conclusions
Low radiation doses in normal organs are more fre-
quently observed in PBT than in IMRT. Assessments of
secondary cancer risk showed that PBT reduces the risk
of secondary cancer in most organs, whereas IMRT is
associated with a slightly larger risk than CRT.
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